Given its inherent time and resource demands, variability in productivity, and the rising complexity of monoclonal antibody (mAb) modalities—including bispecific antibodies (bsAb) and fusion proteins—cell line development (CLD) has become a leading constraint on bioprocess development. CHOvantage™ is a transposon-based CHO-K1 CLD platform designed to meet customer needs, providing a solution for producing stable, high-performing cell lines faster. Using this platform, we generated mAb, bsAb and FC-fusion protein cell lines in less than 4 months with high-titer pools consistently producing up to 5 g/L and correlating clone titers reaching greater than 7 g/L. Selected clones successfully scaled from bench to pilot scale, while maintaining stable expression over more than sixty generations. Product quality attributes also remained consistent across evaluated clones. Collectively, this demonstrates that the CHOvantage™ platform enables rapid, robust, and scalable generation of high-producing cell lines and represents an effective solution for accelerating biotherapeutic development.